Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake

Charalambos Vlachopoulos,Iosif Koutagiar,Ioannis Skoumas,Dimitrios Terentes-Printzios,Evangelos A. Zacharis,Genovefa Kolovou,Kimon Stamatelopoulos,Loukianos S. Rallidis,Niki Katsiki,Helen Bilianou,Evangelos N. Liberopoulos,Antigoni Miliou,Pavlos Kafouris,Aleksandros Georgakopoulos,Vasiliki Gardikioti,Dimitrios Tousoulis,Constantinos Anagnostopoulos

Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake

2019

Charalambos Vlachopoulos
Iosif Koutagiar
Ioannis Skoumas
Dimitrios Terentes-Printzios
Evangelos A. Zacharis
Genovefa Kolovou
Kimon Stamatelopoulos
Loukianos S. Rallidis
Niki Katsiki
Helen Bilianou
Evangelos N. Liberopoulos
Antigoni Miliou
Pavlos Kafouris
Aleksandros Georgakopoulos
Vasiliki Gardikioti
Dimitrios Tousoulis
Constantinos Anagnostopoulos

Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9i) reduce cardiovascular events ([1][1],[2][2]). 18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography/computed tomography (PET/CT) successfully evaluates arterial inflammation and improves

Keywords:

Cardiology
Medicine
Subtilisin
Pharmacology
Kexin
Proprotein convertase
Internal medicine
Arterial Inflammation
Monoclonal antibody
Positron emission tomography
Computed tomography
Pathology
fdg uptake

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations